Rapamycin, also known as Sirolimus, is a macrolide and an inhibitor of the PI3K/Akt/mTOR pathway, a pathway that is often deregulated in cancer [6], which in turn has given Rapamycin potent anti-cancerous properties in a variety of solid tumors and blood-related malignancies [7]. This evidence concerns the gene AKT1 and cancer.